Table. 2.

Table. 2.

Characteristics of patients according to disease phase

Variables Newly diagnosed Persistent Chronic P-value
No. of patients 28 6 11
Age (yr) 3.0±2.6 4.1±2.1 6.9±6.1 0.084
Age group (yr) 0.028
<6 25 (89.3) 5 (83.3) 6 (54.5)
≥6 3 (10.7) 1 (16.7) 5 (45.5)
Sex 0.864
Male 15 (53.6) 5 (83.3) 5 (45.5)
Female 13 (46.4) 1 (16.7) 6 (54.5)
Infection history 0.293
Yes 15 (53.6) 4 (66.7) 8 (72.7)
No 13 (46.4) 2 (33.3) 3 (27.3)
IVIG dose (g/kg) 2.02±0.06 1.99±0.03 1.96±0.09 0.024
IVIG dose (g/kg) 0.011
<2 4 (14.3) 2 (33.3) 6 (54.5)
≥2 24 (85.7) 4 (66.7) 5 (45.5)
Medication >0.999
IVIG only 9 (32.1) 1 (16.7) 4 (36.4)
IVIG+steroid 19 (67.9) 5 (83.3) 7 (63.6)
Laboratory finding
WBC (/mL) 9,800±3,220 7,850±2,930 9,010±4,240 0.273
ALC (/mL) 5,075±2,243 3,795±2,013 4,203±2,657 0.189
Neutrophil (%) 38.7±11.4 40.9±12.6 44.4±16.2 0.215
Lymphocyte (%) 51.5±11.0 46.9±10.1 44.3±16.1 0.105
PLT (/mL) 7,000±4,000 6,000±5,000 9,000±6,000 0.265
ESR (mm/hr) 9±11 5±4 14±16 0.499
CRP (mg/dL) 0.21±0.31 0.31±0.35 6.99±22.56 0.950
AST (IU/L) 46±37 33±6 31±10 0.301
ALT (IU/L) 33±53 15±3 16±6 0.665
LDH (IU/L) 609±113 601±74 553±187 0.570
Bleeding episode
Epistaxis 3 (10.7) 1 (16.7) 1 (9.1) >0.999
Petechiae, bruise 22 (78.6) 6 (100) 9 (81.8) 0.829
GI bleeding 4 (14.3) 0 (0) 0 (0) 0.246
No bleeding 5 (17.9) 0 (0) 2 (18.2) >0.999

IVIG, intravenous immunoglobulin; WBC, white blood cell; ESR, erythrocyte sedimentation rate (normal range: 0-20 mm/hr); CRP, C-reactive protein (normal range: <0.5 mg/dL); LDH, lactate dehydrogenase (normal range: 208-450 IU/L); ALC, absolute lymphocyte count; AST, aspartate aminotransferase (normal range: 10-35 IU/L); ALT, alanine aminotransferase (normal range: 0-40 IU/L); GI, gastrointestinal; PLT, platelet.

Clin Pediatr Hematol Oncol 2022;29:44-51
© 2022 Clin Pediatr Hematol Oncol